← Leaderboards
Jun-Ichi Abe
University Of Tx Md Anderson Can Ctr
$17,528,597
Attributed
$28,095,885
Total exposure
15
Grants
11
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.8M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$28,095,885 · 15
By mechanism
R01$23,260,511 · 13
U01$2,476,340 · 1
P01$2,359,034 · 1
Top collaborators
- Keigi Fujiwara8 shared
- Jay Yang8 shared
- John P Cooke7 shared
- Nhat-Tu Le7 shared
- Sanjay B. Maggirwar5 shared
- Giovanni Schifitto5 shared
- Bradford C Berk4 shared
- Craig N Morrell4 shared
Most similar at University Of Tx Md Anderson Can Ctr
Same institution · by research overlap
- John P Cooke$32,967,803
- Nhat-Tu Le$3,369,101
- Kyung-Sun Heo$383,750
Others in their field
Top investigators on “Mediating”
- Bambra Strokes · Ppd Development Lp$526,656,217
- Lawrence Corey · Fred Hutchinson Cancer Center$493,822,581
- Barton F Haynes · Duke University$295,802,493
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$286,700,869
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$176,977,598
- Dan H. Barouch · Fred Hutchinson Cancer Center$122,734,499
Research focus
MediatingPhosphorylationPlayEventSignal TransductionApoptosisFunctional DisorderAtherosclerosisIn VitroInflammationPreventMolecularInsightBaseIn VivoEndothelial CellsInflammatoryMapk7 GeneNovel Therapeutic InterventionArterial Fatty StreakCardiovascular DiseasesPathway InteractionsLinkReporting
Grant awards (56)
Deciphering the role of GFPT2 in radiation-induced cardiovascular disease$760,982
R01 · FY2025 · HL · contact PI
Premature aging disorders, metabolites, and atherosclerosis$712,298
R01 · FY2025 · HL · contact PI
Premature aging disorders, metabolites, and atherosclerosis$704,737
R01 · FY2024 · HL · contact PI
Mitigating radiation-induced cardiovascular disease by inhibiting premature aging$495,268
U01 · FY2024 · AI · contact PI
Premature aging disorders, metabolites, and atherosclerosis$756,681
R01 · FY2023 · HL · contact PI
Mitigating radiation-induced cardiovascular disease by inhibiting premature aging$495,268
U01 · FY2023 · AI · contact PI
Pathological flow-induced endothelial damage and plaque erosion$782,390
R01 · FY2022 · HL · contact PI
Mitigating radiation-induced cardiovascular disease by inhibiting premature aging$495,268
U01 · FY2022 · AI · contact PI
Pathological flow-induced endothelial damage and plaque erosion$788,251
R01 · FY2021 · HL · contact PI
Mitigating radiation-induced cardiovascular disease by inhibiting premature aging$495,268
U01 · FY2021 · AI · contact PI
Pathological flow-induced endothelial damage and plaque erosion$793,939
R01 · FY2020 · HL · contact PI
Mitigating radiation-induced cardiovascular disease by inhibiting premature aging$495,268
U01 · FY2020 · AI · contact PI
Pathological flow-induced endothelial damage and plaque erosion$829,206
R01 · FY2019 · HL · contact PI
Disturbed flow-induced TERF2IP post-translational modifications and atherosclerosis.$497,282
R01 · FY2019 · HL · contact PI
PAR 13-233 cART accelerates vascular aging in HIV infected subjects$720,374
R01 · FY2018 · HL
Disturbed flow-induced TERF2IP post-translational modifications and atherosclerosis.$497,282
R01 · FY2018 · HL · contact PI
p90RSK-ERK5 module, efferocytosis, and vulnerable plaque formation$400,000
R01 · FY2018 · HL · contact PI
PAR 13-233 cART accelerates vascular aging in HIV infected subjects$729,804
R01 · FY2017 · HL
Disturbed flow-induced TERF2IP post-translational modifications and atherosclerosis.$510,882
R01 · FY2017 · HL · contact PI
p90RSK-ERK5 module, efferocytosis, and vulnerable plaque formation$400,000
R01 · FY2017 · HL · contact PI
PAR 13-233 cART accelerates vascular aging in HIV infected subjects$733,113
R01 · FY2016 · HL
Disturbed flow-induced TERF2IP post-translational modifications and atherosclerosis.$510,882
R01 · FY2016 · HL · contact PI
p90RSK-ERK5 module, efferocytosis, and vulnerable plaque formation$400,000
R01 · FY2016 · HL · contact PI
PAR 13-233 cART accelerates vascular aging in HIV infected subjects$739,353
R01 · FY2015 · HL
p90RSK-ERK5 module, efferocytosis, and vulnerable plaque formation$394,000
R01 · FY2015 · HL · contact PI
PAR 13-233 cART accelerates vascular aging in HIV infected subjects$747,059
R01 · FY2014 · HL
Ubiquitin-like protein modification in diabetic cardiomyopathy$277,704
R01 · FY2014 · HL · contact PI
Ubiquitin-like protein modification in diabetic cardiomyopathy$126,063
R01 · FY2014 · HL · contact PI
Fluid Shear Stress Signal Transduction in Endothelium$448,469
R01 · FY2013 · HL · contact PI
p90RSK: A flow responsive mediator of inflammation$408,347
R01 · FY2013 · HL · contact PI
Ubiquitin-like protein modification in diabetic cardiomyopathy$366,758
R01 · FY2013 · HL · contact PI
Fluid Shear Stress Signal Transduction in Endothelium$464,912
R01 · FY2012 · HL · contact PI
p90RSK: A flow responsive mediator of inflammation$428,935
R01 · FY2012 · HL · contact PI
Ubiquitin-like protein modification in diabetic cardiomyopathy$385,250
R01 · FY2012 · HL · contact PI
Kinases-mediated SUMOylation in Diabetic Cardiomyopathy$501,168
R01 · FY2011 · HL · contact PI
Fluid Shear Stress Signal Transduction in Endothelium$457,770
R01 · FY2011 · HL · contact PI
p90RSK: A flow responsive mediator of inflammation$430,658
R01 · FY2011 · HL · contact PI
Ubiquitin-like protein modification in diabetic cardiomyopathy$398,875
R01 · FY2011 · HL · contact PI
Kinases-mediated SUMOylation in Diabetic Cardiomyopathy$488,243
R01 · FY2010 · HL · contact PI
Fluid Shear Stress Signal Transduction in Endothelium$459,769
R01 · FY2010 · HL
p90RSK: A flow responsive mediator of inflammation$451,802
R01 · FY2010 · HL · contact PI
PPARgamma, Endothelial Inflammation, and Atherosclerosis$497,200
P01 · FY2009 · HL · contact PI
Kinases-mediated SUMOylation in Diabetic Cardiomyopathy$485,124
R01 · FY2009 · HL · contact PI
Kinases-mediated SUMOylation in Diabetic Cardiomyopathy$516,955
R01 · FY2008 · HL · contact PI
PPARgamma, Endothelial Inflammation, and Atherosclerosis$473,112
P01 · FY2008 · HL · contact PI
PPARgamma, Endothelial Inflammation, and Atherosclerosis$468,763
P01 · FY2007 · HL · contact PI
PPARgamma, Endothelial Inflammation, and Atherosclerosis$457,846
P01 · FY2006 · HL · contact PI
PPARgamma, Endothelial Inflammation, and Atherosclerosis$462,113
P01 · FY2005 · HL
PPARgamma, Endothelial Inflammation and Atherosclerosis$390,000
R01 · FY2004 · HL
ROLE OF P90RSK IN DIABETIC CARDIOMYOPATHY$398,750
R01 · FY2003 · HL
ROLE OF P90RSK IN DIABETIC CARDIOMYOPATHY$398,750
R01 · FY2002 · HL
BCR KINASE IN PDGF-MED EFFECTS IN VASCULAR SMOOTH MUSCLE$264,358
R01 · FY2002 · HL
ROLE OF P90RSK IN DIABETIC CARDIOMYOPATHY$398,750
R01 · FY2001 · HL
BCR KINASE IN PDGF-MED EFFECTS IN VASCULAR SMOOTH MUSCLE$256,656
R01 · FY2001 · HL
ROLE OF P90RSK IN DIABETIC CARDIOMYOPATHY$398,750
R01 · FY2000 · HL
BCR KINASE IN PDGF-MED EFFECTS IN VASCULAR SMOOTH MUSCLE$249,180
R01 · FY2000 · HL